Back to search
Diffuse Midline Glioma (DMG)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Diffuse Midline Glioma (DMG) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Diffuse Midline Glioma (DMG) trials you may qualify forThe goal of this clinical research study is to learn about the safety and effects of M032 given directly into the tumor in children and adults with DMG and who…
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse gli…
This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells lentivirally transduced to express a…
The purpose of this study is to assess the feasibility, safety and efficacy of H3K27M-specific engineered immune effector (EIE) therapy in patients with high-ri…
This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas…
This is a phase I, open label, plus expansion clinical trial evaluating the safety and tolerability of rHSC-DIPGVax in combination with BALSTILIMAB and ZALIFREL…
This study is for people (children and adults) with a rare and aggressive brain tumor called H3K27-altered diffuse midline glioma (DMG) located in the pons, a d…
An Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with HGG, especi…